Insider Trading Activity Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) – Major Shareholder Bought 10,000 shares of Stock

ME Staff
-
0

Insider Trading Activity For Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)

Michael Rapp , Major Shareholder of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) reportedly Bought 10,000 shares of the company’s stock at an average price of 9.28 for a total transaction amount of $92,800.00 SEC Form

Insider Trading History For Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)

  • On 8/16/2016 Suzanne M Hanlon, Insider, sold 3,000 with an average share price of $10.53 per share and the total transaction amounting to $31,590.00.
  • On 12/7/2016 James E Fickenscher, CFO, bought 7,000 with an average share price of $14.08 per share and the total transaction amounting to $98,560.00.
  • On 12/29/2016 Michael Rapp, Major Shareholder, bought 10,000 with an average share price of $15.85 per share and the total transaction amounting to $158,500.00.
  • On 5/12/2017 James E Fickenscher, CFO, bought 5,200 with an average share price of $19.82 per share and the total transaction amounting to $103,064.00.
  • On 5/15/2017 Armando Anido, Chairman, bought 5,000 with an average share price of $19.70 per share and the total transaction amounting to $98,500.00.
  • On 10/19/2017 Michael Rapp, Major Shareholder, bought 44,255 with an average share price of $9.59 per share and the total transaction amounting to $424,405.45.
  • On 10/23/2017 Michael Rapp, Major Shareholder, bought 25,745 with an average share price of $9.94 per share and the total transaction amounting to $255,905.30.

    • Analyst Ratings History For Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)

    • On 8/14/2017 Maxim Group Reiterated Rating Hold
    • On 8/15/2017 Jefferies Group Downgraded rating Buy to Hold with a price target of $12.00 to $7.00
    • On 8/15/2017 CIBC Reiterated Rating Outperform to Market Perform
    • On 10/1/2017 Roth Capital Set Price Target of rating Buy with a price target of $15.00 with a price target of $16.00 to $20.00
    • On 12/4/2017 Canaccord Genuity Set Price Target of rating Outperform to Buy with a price target of $15.00 to $18.00
    • On 1/29/2018 Ladenburg Thalmann Financial Services Initiated Coverage of rating Buy to Buy with a price target of $25.50

    Recent Trading Activity for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)
    Shares of Zynerba Pharmaceuticals Inc closed the previous trading session at 9.05 down -0.06 0.66% with 8.859999656677246 shares trading hands.